000305541 001__ 305541
000305541 005__ 20251029115601.0
000305541 0247_ $$2pmid$$apmid:41144997
000305541 0247_ $$2doi$$aDOI:10.3171/CASE25589 
000305541 0247_ $$2doi$$aDOI:10.3171/CASE25589
000305541 037__ $$aDKFZ-2025-02215
000305541 041__ $$aEnglish
000305541 082__ $$a610
000305541 1001_ $$aNiedermeyer, Sebastian$$b0
000305541 245__ $$aPET imaging pitfall in recurrent oligodendroglioma with drug-resistant epilepsy: illustrative case.
000305541 260__ $$aCharlottesville, Va.$$bAmerican Association of Neurological Surgeons$$c2025
000305541 3367_ $$2DRIVER$$aarticle
000305541 3367_ $$2DataCite$$aOutput Types/Journal article
000305541 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1761658511_3682426
000305541 3367_ $$2BibTeX$$aARTICLE
000305541 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000305541 3367_ $$00$$2EndNote$$aJournal Article
000305541 520__ $$aMRI and PET imaging using radiolabeled amino acids offer a valuable adjunct for defining the extent of tumor growth in gliomas, assessing treatment response, and distinguishing true progression from pseudoprogression.The authors report the case of a 37-year-old patient with intractable epilepsy and suspected recurrence of an oligodendroglioma. MRI revealed progressive gadolinium enhancement in the right frontal lobe, and both fluorethylthyrosine PET and translocator protein imaging demonstrated high tracer uptake in the same region, raising concern for tumor recurrence and progression. The patient underwent extensive resection of the right frontal lobe beyond contrast enhancement. Postoperatively, seizures were well controlled. Interestingly, histopathological analysis revealed predominantly normal brain tissue next to a limited area of tumor recurrence, demonstrating that the observed MRI and PET abnormalities were seizure-induced changes rather than tumor recurrence.In patients with epileptic seizures, MRI and PET abnormalities may overestimate tumor recurrence and should be interpreted with caution. https://thejns.org/doi/10.3171/CASE25589.
000305541 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000305541 588__ $$aDataset connected to DataCite, PubMed, , Journals: inrepo02.dkfz.de
000305541 650_7 $$2Other$$aPET imaging
000305541 650_7 $$2Other$$aepilepsy
000305541 650_7 $$2Other$$aoligodendroglioma
000305541 7001_ $$aSchmutzer-Sondergeld, Michael$$b1
000305541 7001_ $$00000-0001-6864-3369$$aKirchleitner, Sabrina V$$b2
000305541 7001_ $$00000-0003-2914-3649$$aQuach, Stefanie$$b3
000305541 7001_ $$0P:(DE-HGF)0$$aAlbert, Nathalie L$$b4
000305541 7001_ $$aThon, Niklas$$b5
000305541 773__ $$0PERI:(DE-600)3106696-3$$aDOI:10.3171/CASE25589$$gVol. 10, no. 17$$n17$$pCASE25589$$tJournal of neurosurgery / Case lessons$$v10$$x2694-1902$$y2025
000305541 909CO $$ooai:inrepo02.dkfz.de:305541$$pVDB
000305541 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000305541 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000305541 9141_ $$y2025
000305541 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-16
000305541 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-16
000305541 9201_ $$0I:(DE-He78)MU01-20160331$$kMU01$$lDKTK Koordinierungsstelle München$$x0
000305541 980__ $$ajournal
000305541 980__ $$aVDB
000305541 980__ $$aI:(DE-He78)MU01-20160331
000305541 980__ $$aUNRESTRICTED